◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksNVO › Net Income

Novo Nordisk A/S (NVO) Net Income 2006–TTM

DATA UPDATED 2026-07-19

Novo Nordisk A/S annual net income for fiscal TTM was $122.0 billion, an increase of 19.1% from $102.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

NVO Annual Net Income

Net Income (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Net Income$122.0B$102.4B$101.0B$83.7B$55.5B$47.8B$42.1B$39.0B$38.6B$38.1B$37.9B$34.9B$26.5B$25.2B$21.4B$17.1B$14.4B$10.8B$9.7B$8.5B$6.5B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVO Quarterly Net Income

Net Income (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Net Income$48.6B$26.9B$20.0B$26.5B$29.0B$28.2B$27.3B$20.1B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More NVO metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All NVO financial statements → Interactive NVO charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.